Log in

Industry News

FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy

On March 3, 2023, the U.S Food and Drug Administration (FDA) approved an expanded indication for abemaciclib, in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at a high risk of recurrence. 

For more information read the FDA announcement and the Lilly Oncology announcement

Posted 3/6/2023

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us